124391-60-2

Usage

Uses

Used in Organic Synthesis:
4-Nitro-2-phenylbenzoic acid is used as a building block in organic synthesis for the creation of more complex molecules, leveraging its structural properties to form a variety of chemical compounds.
Used in Pharmaceutical Research:
In pharmaceutical research, 4-Nitro-2-phenylbenzoic acid is utilized as a precursor for the development of new drugs, particularly due to its potential anti-inflammatory and antitumor properties, which are under investigation for therapeutic applications.
Used in the Development of New Materials:
4-Nitro-2-phenylbenzoic acid is employed in the development of innovative materials, capitalizing on its chemical properties to enhance or create materials with specific characteristics for various industrial applications.
Used as a Reagent in Chemical Reactions:
4-Nitro-2-phenylbenzoic acid also serves as a reagent in a range of chemical reactions, facilitating processes that require its unique chemical structure to achieve desired outcomes in the synthesis of other compounds.

Upstream product

• 6326-42-7 2-iodo-4-nitrobenzoic acid methyl ester 
• 591-50-4 iodobenzene 
• 62-23-7 4-nitro-benzoic acid 
• 124391-54-4 2-(bromomethyl)-5-nitro-1,1'-biphenyl 
• 98-80-6 phenylboronic acid 
• 7745-93-9 2-bromo-4-nitrotoluene 
• 64-19-7 acetic acid 
• 13480-38-1 4-Nitro-2-phenyltoluene 
• 124391-58-8 2-Formyl-5-nitrobiphenyl 

Downstream Products

• 42135-22-8 3-nitro-9H-fluoren-9-one 
• 191101-08-3 [4-(3-pyridylmethylamino)-2-phenylbenzoyl]homoserine lactone 
• 489409-89-4 5-nitro-biphenyl-2-carboxylic acid cyclohexyl ester 
• 58084-75-6 9-hydroxy-3-nitrofluorene 
• 180977-36-0 (S)-2-{[5-((R)-2-tert-Butoxycarbonylamino-3-tritylsulfanyl-propylamino)-biphenyl-2-carbonyl]-amino}-4-methyl-pentanoic acid methyl ester 
• 205590-50-7 (2S,3S)-2-{[5-((R)-2-tert-Butoxycarbonylamino-3-tritylsulfanyl-propylamino)-biphenyl-2-carbonyl]-amino}-3-methyl-pentanoic acid methyl ester 
• 205590-51-8 (S)-2-{[5-((R)-2-tert-Butoxycarbonylamino-3-tritylsulfanyl-propylamino)-biphenyl-2-carbonyl]-amino}-hexanoic acid methyl ester 
• 655234-96-1 2-({5-[(3-biphenyl-4-ylmethyl-3H-imidazol-4-ylmethyl)-amino]-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyric acid methyl ester 
• 655235-64-6 4-[N-(1-(4-phenyl)benzyl-1H-imidazol-4-yl)methylamino]-2-phenylbenzoylmethionine methyl ester 
• 880106-49-0 4-[N-(1-(1-naphthyl)methyl-1H-imidazol-4-yl)methylamino]-2-phenylbenzoylmethionine methyl ester 
• 655235-66-8 4-[N-(1-cyclohexylmethyl-1H-imidazol-4-yl)methylamino]-2-phenylbenzoylmethionine methyl ester 
• 655235-70-4 4-[N-(1-cyclohexylmethyl-1H-imidazol-5-yl)methylamino]-2-phenylbenzoylmethionine methyl ester 
• 655234-30-3 2-[(5-{[3-(4-cyano-benzyl)-3H-imidazol-4-ylmethyl]-amino}-biphenyl-2-carbonyl)-amino]-4-methylsulfanyl-butyric acid methyl ester 

Relevant academic research and scientific papers

Synthesis and radiofluorination of novel fluoren-9-one based derivatives for the imaging of α7 nicotinic acetylcholine receptor with PET

By structure–activity relationship studies on the tilorone scaffold, the ‘one armed’ substituted dibenzothiophenes and the fluoren-9-ones were identified as the most potential α7 nAChR ligands. While the suitability of dibenzothiophene derivatives as PET tracers is recognized, the potential of fluoren-9-ones is insufficiently investigated. We herein report on a series of fluoren-9-one based derivatives targeting α7 nAChR with compounds 8a and 8c possessing the highest affinity and selectivity. Accordingly, with [18F]8a and [18F]8c we designed and initially evaluated the first fluoren-9-one derived α7 nAChR selective PET ligands. A future application of these radioligands is facilitated by the herein presented successful implementation of fully automated radiosynthesis.

Exploration of Biaryl Carboxylic Acids as Proton Shuttles for the Selective Functionalization of Indole C-H Bonds

A survey of diversely substituted 2-arylbenzoic acids were synthesized and tested for use as proton shuttle in the direct arylation of indoles with bromobenzenes. It was found that 3-ethoxy-2-phenylbenzoic acid gives superior yield and selectivity for this class of substrates.

General and practical carboxyl-group-directed remote C-H oxygenation reactions of arenes

Two methods for remote aromatic C-H oxygenation reactions, have been developed. Method1, the Cu-catalyzed oxygenation reaction, is highly efficient for cyclization of electron-neutral and electron-rich biaryl carboxylic acids into 3,4-benzocoumarins. Method2, the K2S2O 8-mediated oxygenation reaction, is more general and practical for cyclization of substrates with electron-donating and -withdrawing groups (see scheme). Copyright

Structurally simple inhibitors of lanosterol 14α-demethylase are efficacious in a rodent model of acute Chagas disease

We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14α-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T. cruzi amastigotes in vitro with values of EC 50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.

N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES

The invention relates to N-thiazol-2-yl-benzamide derivatives of the formula I in the description wherein the variables are as defined in the claims. The compounds are A2A-receptor ligands, such as antagonists, agonists, reverse agonists or partial agonists, and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated.

Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity

Malaria continues to represent a very serious health problem in the tropics. The current methods of clinical treatment are showing deficiencies due to the increased incidence of resistance in the parasite. In the present paper we report the design, synthe

Probing the hydrophobic pocket of farnesyltransferase: Aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors

Cysteine farnesylation at the carboxylate terminal tetrapeptide CAAX of Ras protein is catalyzed by farnesyltransferase. This lipid modification is necessary for regulatory function of both normal and oncogenic Ras. The high frequency of Ras mutation in human cancers has prompted an intensive study on finding ways of controlling oncogenic Ras function. Inhibition of farnesyltransferase is among the most sought after targets for cancer chemotherapy. We report here the design, synthesis and biological characterization of a series of peptidomimetics as farnesyltransferase inhibitors. These compounds are extremely potent towards farnesyltransferase with IC50 values ranging from subnanomolar to low nanomolar concentrations. They have a high selectivity for farnesyltransferase over the closely related geranylgeranyltransferase-I. Structure-activity relationship studies demonstrated that a properly positioned hydrophobic group significantly enhanced inhibition potency, reflecting an improved complementarity to the large hydrophobic pocket in the CAAX binding site. Copyright (C) 1999 Elsevier Science Ltd.

Inhibitors of prenyl transferases

Compounds which inhibit prenyl transferases, particularly farnysyltransferase and geranylgeranyl transferase I, processes for preparing the compounds, pharmaceutical compositions containing the compounds, and methods of use.

Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase

Potent and selective non-thiol-containing inhibitors of protein farnesyltransferase are described. FTI-276 (1) was transformed into pyridyl ether analogue 19. The potency of pyridyl ether 19 was improved by modification of the biphenyl core to that of an

Inhibitors of farnesyltransferase

Peptidomimetics of the formula CβX where C is cysteine, X is any naturally occuring amino acid, and β is a hydrophobic spacer, most notably 2-phenyl-4-aminobenzoic acid. These compounds are effective inhibitors of p2lras farnesyltrasferase, block Ras-dependent oncogenic signalling and inhibit human tumor growth in vivo in animal models. Pro-drugs made by functionalizing terminal amino and carboxylic acid groups of peptides and peptidomimetics are also disclosed. Such functionalized derivatives demonstrate increased cell uptake. Other structural modifications are also disclosed.